Chronic Kidney Disease with IgA Nephropathy or Diabetes Study

Chronic Kidney Disease with IgA Nephropathy or Diabetes Trials in Phoenix

Centricity Research is currently participating in a study for people who have chronic kidney disease with IgA nephropathy or diabetes at at our Phoenix, AZ location. Chronic kidney disease (CKD) describes the gradual loss of kidney function. Treatment for CKD focuses on slowing the progression of kidney damage, usually by controlling the underlying cause. Diabetes is the leading cause of kidney failure, accounting for 44% percent of new cases. Current research suggests that control of high blood pressure is a key factor in slowing this disease. IgA nephropathy (also known as Berger’s disease) is one of the most common kidney diseases. It causes damage to the tiny filters inside the kidneys. This damage can cause CKD and can lead to kidney failure. Advances in drug therapies for these indications are key to treating this disease at its early stages and preventing further damage.

Enroll Now

Chronic Kidney Disease with IgA Nephropathy or Diabetes Clinical Trial

The objective of this study is to evaluate the safety, efficacy, tolerability, PD, and PK profile of an investigational drug in patients with chronic kidney disease with IgA nephropathy or diabetes. You maybe be eligible to participate in this study if you are at least 18 years of age, have chronic kidney disease and meet ONE of the three following criteria:

• be African American with hypertension

OR

• have IgA nephropathy

OR

• have type 2 diabetes with hypertension